Selected passages from the FDA letter
Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.
Passage 1The sponsored links are misleading because they include representations about the efficacy of Relexxii but fail to communicate any risk information.
Citations in the original letter
As cited in this historical letter, not a statement of current regulatory requirements.
- 21 CFR 202.1